glp-1 pediatric GLP‐1 Agonists for Psychopharmacology: Opportunities and Cautions Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Retatrutide Dosage in Clinical Trials The primary source of dosage data for retatrutide comes from the Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023)

If youre considering GLP-1s, have an honest conversation with your provider, share your full history, and weigh the pros and cons carefully

Phase 2 trial data have explored weekly subcutaneous doses ranging from 1 mg to 12 mg, administered via a gradual escalation schedule

& Schmidt, W

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

T., Haavik, J., Klungsyr, K., & Engeland, A